ContraVir Pharmaceuticals

April 6, 2017April 6, 2017

ContraVir Reports New Mechanism of Action for Hepatitis B Virus Inhibitor CRV431

Hepatitis B, News

ContraVir Pharmaceuticals, a New Jersey-based biopharma company that develops and commercializes antiviral therapies, is providing new insights into the mechanism of action of its hepatitis B virus (HBV)-optimized cyclophilin inhibitor CRV431. ... Read more

January 5, 2017January 5, 2017

ContraVir Awarded $224K Research Grant to Advance Potential Hepatitis B Treatment

Hepatitis B, News

The National Research Council (NRC) in Canada has awarded ContraVir Pharmaceuticals more than $224,000 to cover expenses related to the preclinical development of CRV431, the company’s cyclophilin inhibitor for the treatment of hepatitis B virus (HBV). The research award, ... Read more

October 18, 2016October 18, 2016

ContraVir’s Lead Hepatitis B Candidate Advances in Phase 2a Trial

Hepatitis B, News

ContraVir has begun patient enrollment for the next dosing group in its Phase 2a clinical trial comparing the company’s CMX157 with Viread (tenofovir disoproxil fumarate) to treat chronic hepatitis B ... Read more

June 28, 2016June 28, 2016

First Hepatitis B Patients Treated in Study of New Therapy at Lower Doses Than Standard

Hepatitis B, News

ContraVir Pharmaceuticals announced the dosing of the first patients with chronic hepatitis B enrolled in its head-to-head Phase 2a clinical trial comparing multiple doses of the company’s lead candidate CMX157 to tenofovir disoproxil fumarate (TDF), a standard therapy. ... Read more